Pangenomic Health Inc.
Pangenomic Health Inc. operates as a precision health company in Canada. The company offers Nara App, a telehealth mental health app that provides users with personalized information about non-pharmaceutical alternatives to address mental health concerns; and Mindleap, a telehealth platform, which provides various tools and resources to help individuals understand and improve their inner wellness… Read more
Pangenomic Health Inc. (LL3) - Net Assets
Latest net assets as of September 2025: €-1.77 Million EUR
Based on the latest financial reports, Pangenomic Health Inc. (LL3) has net assets worth €-1.77 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€270.90K) and total liabilities (€2.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.77 Million |
| % of Total Assets | -654.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Pangenomic Health Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Pangenomic Health Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pangenomic Health Inc. (2021–2024)
The table below shows the annual net assets of Pangenomic Health Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-2.41 Million | -12.16% |
| 2023-12-31 | €-2.14 Million | -896.98% |
| 2022-12-31 | €-215.11K | -109.59% |
| 2021-12-31 | €2.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pangenomic Health Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1877109000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €19.35 Million | % |
| Total Equity | €-2.41 Million | 100.00% |
Pangenomic Health Inc. Competitors by Market Cap
The table below lists competitors of Pangenomic Health Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scandium Canada Ltd
PINK:SCDCF
|
$4.82 Million |
|
Evolva Holding SA
PINK:ELVAF
|
$4.82 Million |
|
SE-Education Public Company Limited
BK:SE-ED
|
$4.82 Million |
|
Binect AG
XETRA:MA10
|
$4.82 Million |
|
MAST ENERGY DEV. LS -001
F:97D
|
$4.81 Million |
|
Plaza Wires Limited
NSE:PLAZACABLE
|
$4.81 Million |
|
CoinSmart Financial Inc
NEO:SMRT
|
$4.81 Million |
|
Key ASIC Bhd
KLSE:0143
|
$4.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pangenomic Health Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,144,604 to -2,405,462, a change of -260,858.
- Net loss of 3,803,848 reduced equity.
- Other factors increased equity by 3,542,990.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.80 Million | -158.13% |
| Other Changes | €3.54 Million | +147.29% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Pangenomic Health Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.41 | €0.27 | x |
| 2022-12-31 | €-0.11 | €0.27 | x |
| 2023-12-31 | €-1.02 | €0.27 | x |
| 2024-12-31 | €-0.38 | €0.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pangenomic Health Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-29.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -118.14% | 0.00% | 0.00x | 1.15x | €-2.87 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-11.97 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.76 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-3.56 Million |
Industry Comparison
This section compares Pangenomic Health Inc.'s net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $2,007,889,576
- Average return on equity (ROE) among peers: -0.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pangenomic Health Inc. (LL3) | €-1.77 Million | -118.14% | N/A | $4.82 Million |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $371.65K |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $18.00 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |